

WARPNINE

Charging at warp speed to find the cancer treatments of the future!

ANNUAL REVIEW

FINANCIAL YEAR 2022- 2023




Table of Contents

- 
- 03** About WARPNINE
 - 04** Mission and Vision
 - 05** Understanding gastro-intestinal and rare cancers
 - 06** The Current Situation: A Stark Reality
 - 07** Our Strategic Focus
 - 07** Objectives
 - 09** Key Actions to Achieve Our Objectives
 - 10** Our Projects and Impact
 - 12** Chair Report
 - 13** CEO Report
 - 14** Our Supporters
 - 16** How You Can Support Us
 - 18** Financial Statements

About WARPINE

WARPINE is Western Australia's research into pancreatic, gastro-intestinal, and rare cancers.

Born from the vision of Dr Andrew Dean, a distinguished Oncologist in Western Australia, our foundation emerged in May 2021. Driven by the urgent recognition of a growing demand for dedicated research, heightened awareness, and unwavering support for individuals and families grappling with the relentless challenges posed by pancreatic, gastro-intestinal, and rare cancers.

We owe our existence to the incredible generosity of our founding donors. Their remarkable commitment has empowered us to make a real difference. We are on a relentless mission to raise essential funds, paving the way for translational research that swiftly transforms groundbreaking discoveries from laboratory settings into life-changing bedside solutions. Our focus extends to clinical research, fostering immediate, real-world clinical trials that directly impact patient well-being and enhance the lives of those impacted.

But we don't stop there. We're committed to projects that not only better the present but also secure a healthier and brighter future for Western Australians and those around the world affected by these insidious diseases. Together, we're fighting to defeat cancer and improve the health and well-being of countless lives.

WARPINE Board and CEO



Dr Andrew Dean
Chair and Medical Oncologist



Mr Richard Scragg
Director



Mr Neil Rae
Deputy Chair



Mr Vic Jakovich
Director



Mr Tony Mckenna
Treasurer



Hon. Liza Harvey
Director



Mr Bill James
Secretary



Mrs Meg Croucher
CEO

Mission and Vision

We are a small, dedicated team committed to making a measurable difference to the outcomes and survival rates for pancreatic, gastro-intestinal and rare cancers.



Mission


We seek to address the inequity in cancer outcomes for what are essentially underfunded and under-researched malignancies, and we are committed to providing real and meaningful benefit to patients, while building on Western Australia's best-in-the-world outcomes for these cancers.

Vision

To pioneer a future where patients receive early access to groundbreaking clinical trials, where leading researchers and specialists are equipped to facilitate the seamless translation of laboratory findings into practical bedside applications, and specialised projects are initiated, directly improving the well-being of patients. Ultimately, we aspire to catalyse a transformation, turning these once-devastating cancers into curable diseases.

Understanding gastro-intestinal and rare cancers

Despite being primary contributors to cancer-related fatalities, gastro-intestinal and rare cancers remain critically underfunded and undersupported. Their limited visibility is exacerbated by patients' tragically brief life expectancy post-diagnosis.



Photomicrograph of CT scan-guided fine needle aspirate (FNA) cytology of a pancreatic mass showing malignant cells indicating adenocarcinoma.

Gastro-intestinal

Gastro-intestinal cancer collectively refers to a group of malignancies affecting the digestive system. These cancers impact vital organs such as the esophagus, stomach, liver, gallbladder, biliary tract, pancreas, large and small bowel, rectum, and anus. These organs play pivotal roles in food and fluid digestion, nutrient processing, energy absorption, blood sugar regulation, and waste elimination.

Rare

Rare cancers encompass over 200 different types, with an incidence rate of less than 6 cases in 100,000 Australians per year. Less common cancers have an incidence rate between 6 and 12 cases per 100,000 Australians annually. Astonishingly, while individual occurrences may seem low, together, rare and less common cancers account for 38% of all cancer deaths in Australia.

*AIHW Australian Cancer Database 2019 and National Mortality Database


The Current Situation: A Stark Reality

To cut to the chase, the situation is grim:

Gastro-intestinal and rare cancers collectively rank as the most prevalent cancers in Australia. They are a leading cause of cancer-related deaths, with treatment options and survival rates significantly lagging behind more common cancers due to insufficient funding and awareness.

Ideally, the distribution of research funding for different types of cancer should be equitable with respect to the societal burden each type of cancer imposes. However, if we compare the latest figures presented by the Australian Institute of Health and Welfare, it is clear that this is not the case.


■ Comparative Percentage of Government Funding 2019-2020 \$M
 ■ 5-year Survival Rate From Diagnosis 2015-2019




Australian Institute of Health and Welfare (2022) Disease expenditure in Australia 2019–20, AIHW, Australian Government, accessed 18 September 2023.

FIVE-YEAR CANCER SURVIVAL


of persons (all ages) from diagnosis in 2015-2019




ALL CANCERS COMBINED




PANCREATIC CANCER



GALLBLADDER & EXTRAHEPATIC BILE DUCT CANCER



OESOPHAGEAL CANCER



STOMACH CANCER

Australian Institute of Health and Welfare (2023) Cancer data in Australia, AIHW, Australian Government, accessed 18 September 2023.

Adding to the challenge, the pursuit of critical funding from the National Health and Medical Research Council (NHMRC), the main statutory authority of the Australian Government responsible for medical research, imposes a stringent requirement—studies must be at least 80% complete to be deemed competitive.

This rigorous standard poses a major challenge for researchers studying low-survival cancers like pancreatic, rare, and gastro-intestinal malignancies, where preliminary data is often scarcer compared to more common cancers with better outcomes. This glaring inequity starkly hampers the allocation of essential funding to combat these malignancies.

WARPNINE stands as a beacon of hope, dedicated to securing philanthropic funding, driving translational research, pioneering patient-centred initiatives, and expediting clinical trials for immediate patient benefits. Our mission is to rectify disparities in outcomes for those facing challenging cancers.

Gastro-intestinal and rare cancer treatment is complex, demanding a multifaceted approach including surgery, radiotherapy, and chemotherapy. Clinical trials are at the forefront of progress, meticulously crafting optimal treatments tailored to real individuals.

These trials are not confined to labs; they impact lives, charting a course toward compassionate care. Conducting trials in Australia provides patients access to cutting-edge treatments years ahead of international peers, offering a brighter tomorrow for those with gastrointestinal and rare cancers.

Our commitment is clear: we're agile, future-focused, and dedicated to prioritising patient care and outcomes. With the support of generous donors and corporate partners, we aim to reduce cancer outcome disparities, especially in gastro-intestinal and rare cancers, while building upon Western Australia's research successes.

Western Australian researchers have been at the forefront of pioneering cancer treatments. Your support allows us to continue our relentless pursuit of cutting-edge cancer treatments, improving survival rates and patient outcomes for these challenging and often fatal cancers. Dedication, skill, and tenacity are essential to our mission, and we can only achieve our ambitious goals with your backing.

We concentrate our support in three critical areas:

1. Clinical Trials: Accelerating the development of new interventions to benefit patients in Western Australia and beyond.

2. Translational Research: Transforming the future of medicine for pancreatic, gastro-intestinal, and rare cancers through funding new treatments and diagnostics, translating discoveries into better healthcare and outcomes.

3. Innovative Projects and New Technologies: Developing effective treatments for underfunded malignancies and investing in state-of-the-art technologies to enhance patient outcomes.

Our Strategic Focus

At WARPINE, our strategic focus has consistently centred on six core strategies dedicated to improving the outcomes of those affected by pancreatic, gastro-intestinal, and rare cancers.

Improve Health and Well-being:

Improve the health and well-being of people impacted by underfunded and under-researched malignancies.

Create Capacity:

Fundraise successfully and manage finances carefully.

Be Known:

Build a well-respected brand known for being agile, innovative, progressive, and patient outcome-oriented.

Create Awareness:

Advocate for people impacted by underfunded and under-researched malignancies to support earlier diagnosis and raise funds for translational research.

Govern Well:

Ensure our organisation is above reproach.

Value our people:

Ensure our team is skilled, supported, motivated and effective.

Objectives

To relentlessly push the boundaries, propelling Western Australia's unparalleled cancer outcomes even higher for those grappling with challenging, underfunded, and under-researched malignancies.

To champion research and clinical trials with a laser-focused aim: to swiftly and significantly improve patient survival and well-being, delivering tangible results in both the immediate and enduring future.

To ignite a fire of awareness, shedding light on the formidable challenges posed by pancreatic, gastro-intestinal, and rare diseases, sparking empathy, understanding, and action.

Key Actions to Achieve Our Objectives

Champion Revolutionary Clinical Trials:

We will fervently back groundbreaking clinical trials that directly benefit patients, ushering in a new era of treatment possibilities.

Accelerate Clinically Meaningful Research:

We will provide unwavering support to research efforts that yield swift and tangible benefits for patients, ensuring real-world impact.

Amplify Awareness and Advocate for Change:

We will raise a resounding voice to spotlight the challenges posed by pancreatic, gastrointestinal, and rare cancers. Our advocacy will drive change, addressing funding disparities, fostering early diagnosis, and ultimately improving patient outcomes.

Elevate Patient-Centric Care:

We will tirelessly work to elevate the standards of patient care, ensuring the holistic needs of patients and their families are met with excellence.

Empower Future Leaders:

We will invest in nurturing the leaders of tomorrow, attracting the brightest minds to the realm of pancreatic, gastrointestinal, and rare cancer research.

Pioneer Innovative, Personalized Therapies:

Our commitment extends to driving the discovery and application of cutting-edge, personalised treatments and therapies, reducing cancer recurrence and enhancing individualised care.



Our Projects and Impact

Your Support in Action

Each and every dollar you contribute assumes a pivotal role in propelling us towards the discovery of future cancer treatments and, most importantly, in elevating the survival rates of these profoundly challenging and often life-threatening cancers. With the unwavering support of individuals like you, our mission is within reach. Here, we highlight a selection of recent trials and projects that have been made possible through the invaluable contributions of our dedicated donors.

WARPNINE Research Fellow

Your unwavering financial support empowered us to appoint a research fellow committed to advancing under-resourced and under-funded clinical trials for gastro-intestinal and rare cancers. Currently, our Research Fellow's focus is unravelling the gut microbiome's mysteries in pancreatic cancer patients, aiming to predict chemotherapy responses and pave the way for personalised treatments.

Your support transcends science; it saves lives. Success in this pioneering research could significantly enhance chemotherapy effectiveness, ultimately elevating patient survival rates. This initiative marks a historic milestone—the first-ever analysis of the gut microbiome in pancreatic cancer patients within a clinical trial.

Your commitment is the driving force propelling this transformative journey in cancer care. Thank you for making an impact that extends well beyond the laboratory, offering hope and healing to those in need.

National Biliary Cancer Registry

Your support has played a pivotal role in establishing the National Biliary Cancer Registry in collaboration with esteemed institutions such as Monash University, The Australasian Gastrointestinal Trials Group (AGITG), PANCARE Foundation, the Australian and New Zealand Hepato-Pancreatico-Biliary Association (ANZHPBA), and BioGrid Australia. This registry meticulously gathers data on biliary cancer diagnosis, treatment, and outcomes with the goal of improving patient care standards.

Your continued support has propelled our charity toward achieving its mission to address cancer disparities and provide meaningful benefits to patients. Your profound impact on the fight against cancer is deeply appreciated.


i-LSTA Clinical Trial

Thanks to your incredible generosity, we've embarked on a truly groundbreaking journey in the realm of pancreatic cancer. Your contributions have fuelled a pioneering clinical trial, one that holds the promise of transforming lives and rewriting the story of hope for those battling locally advanced pancreatic ductal adenocarcinoma (PDAC).

This extraordinary study focuses on the remarkable potential of LSTA1, a cutting-edge cancer treatment. We're combining it with chemotherapy and immunotherapy to form a formidable alliance against this formidable adversary. Your unwavering support has made it possible for us to delve deep into the safety and potential impact of LSTA1 when joined with established treatments.

The possibilities are nothing short of awe-inspiring. Should this approach prove both safe and effective, it has the power to revolutionise the very landscape of pancreatic cancer treatment. It holds the key to brighter tomorrows, offering renewed hope and significantly improved outcomes for patients facing the darkest of challenges.

Your compassion and commitment have set in motion a journey toward a brighter, more hopeful future for those affected by this devastating disease. Your generosity shines as a beacon of light in the fight against pancreatic cancer.



Chair Report

Together, we are charging at warp speed to find the cancer treatments of the future.



Dear Members and Supporters,

It's with immense pride and gratitude that I present you with our first Annual Report. As we reflect on the remarkable journey we've embarked upon in our relentless pursuit of progress against pancreatic, gastro-intestinal, and rare cancers. This journey, born out of a sense of urgency and the recognition of a growing demand for dedicated research and funding, has been nothing short of extraordinary.

As an Oncologist here in Western Australia, I witnessed firsthand the challenges faced by patients battling these underfunded malignancies. It was clear that we needed to do more, to move faster, and to push the boundaries of what's possible. Thus, WARPnine was born, driven by the unwavering belief that we can make a difference.

The financial support we have received from individuals, institutions, and the community at large, has been nothing short of awe-inspiring. Your dedication has allowed us to initiate patient-focused clinical trials that have the potential to redefine the future of cancer treatment. It's your generosity that has made these trials possible, and for that, we are profoundly grateful.

We have made remarkable strides, yet the road ahead calls for even greater determination and urgency. Western Australia stands proudly at the forefront, boasting best-in-the-world outcomes for these cancers, but we must continue at warp speed to build upon these achievements.

Our mission is crystal clear: to improve treatment options, enhance outcomes, and elevate survival rates for those battling these formidable diseases. We're determined to bridge the gap in research and funding, ensuring that no patient faces a future defined by the limitations of their diagnosis.

In closing, I want to express my deep gratitude to each and every one of you. Your unwavering support and commitment are the driving force behind our mission. Together, we are making a profound impact on the lives of those affected by pancreatic, gastrointestinal, and rare cancers. Let's continue this journey with unwavering resolve, for the benefit of patients, their families, and our community. The challenges are great, but so is our determination.

With sincere gratitude and humility,

A handwritten signature in black ink that reads "Andrew Dean". The signature is written in a cursive, slightly slanted style.

Dr Andrew Dean

Chair and Medical Oncologist

CEO Report

Together, we are making a meaningful and lasting difference in the world of cancer research and patient care.



Dear Friends and Supporters,

I am deeply moved and inspired by the incredible impact your generosity has on the lives of those affected by pancreatic, gastro-intestinal, and rare cancers. Your dedication to our cause is nothing short of remarkable, and it is my privilege to share with you the profound significance of your support.

Pioneering Clinical Advancements: Your contributions have enabled us to embark on groundbreaking initiatives that hold the promise of rewriting the story of hope for individuals facing these challenging cancers. Through your support, we've ventured into uncharted territories of cancer research and patient care. The potential breakthroughs we are pursuing are nothing short of awe-inspiring, with the potential to revolutionise treatment approaches and outcomes.

Saving Lives Through Science: Your commitment transcends science itself; it is a lifeline. The impact of your support extends far beyond the laboratory. It is felt in the hearts and lives of patients and their families. The work we are undertaking, whether in pioneering clinical trials, unravelling the mysteries of the gut microbiome, or establishing vital cancer registries, has the potential to save lives. Your dedication is the driving force propelling these transformative journeys in cancer care.

Collaborative Progress: Together, we have formed powerful partnerships with esteemed institutions and organisations. Your partnership and support have been pivotal in fostering collaboration and innovation. It is through these collaborations that we are able to gather data, improve patient care standards, and address disparities in cancer research and treatment. Your continued support has been instrumental in advancing our mission.

Gratitude Beyond Words: Please know that your profound impact on the fight against cancer is deeply appreciated. The individuals and families affected by these challenging cancers are beneficiaries of your compassion and commitment. Your generosity leads them to a brighter, more hopeful future.

In conclusion, I want to express my heartfelt gratitude for your unwavering support. Your contributions are the lifeblood of our organisation and the source of hope for countless individuals facing these devastating cancers.

With deepest appreciation,

A handwritten signature in black ink, appearing to read 'Meg Croucher'. The signature is fluid and cursive, written over a light blue horizontal line.

Meg Croucher
Chief Executive Officer

Founding Supporters

WARPNINE is deeply grateful for the unwavering support and vision of our founding supporters. Their commitment and foresight have laid the cornerstone for our mission to bridge the funding and research gaps in pancreatic, gastro-intestinal, and rare cancers. Their belief in our cause has been pivotal, and their generosity has propelled us forward on this challenging journey. We extend our heartfelt appreciation for their instrumental role in making our mission a reality and shaping a brighter future for all those affected by these diseases.





Supporters

WARPNINE is grateful to have received generous support from the following individuals and organisations who made cumulative gifts of \$10,000 and above during the last two financial years.

Anonymous
 Bendat Family Foundation
 Carcione Foundation
 Chantelle Somas
 Fenchurch Insurance
 Jako Industries
 Jenaya and Richard Scragg
 Jillian and Ian Green

John Carrigg
 Kerimi Family Foundation
 Leivick Nominees Pty Ltd
 Lisata Therapeutics
 Terry Iannello
 The Rae Family Foundation
 WAMO

We also extend our heartfelt thanks to our volunteers and community fundraisers – without you our work would not be possible.

How You Can Support Us

We are committed to advancing patient care through early access to clinical trials, funding essential research, and supporting specialised projects that benefit patients and their families directly.

At WARPINE, our mission to address inequalities in cancer outcomes is made possible through the incredible support of our community. There are multiple avenues through which you can contribute and become a crucial part of our journey:


Fundraise for WARPINE

Become a WARPINE fundraising hero by creating a personalised fundraising page. Your unique ideas can support us in discovering future treatments for pancreatic, gastrointestinal, and rare cancers. Share your page with family, friends, and colleagues to receive donations easily.

Tributes

Use your donation to pay tribute to someone, celebrate a significant event, or create a lasting legacy in memory of a loved one. Your contributions will help us build on our successes and continue to improve survival rates for challenging cancers.

- **Gifts in Memory:** Honor the life and legacy of a loved one by making a gift in their memory. This special tribute supports revolutionary research, making a meaningful difference for future generations.
- **Gifts in Celebration:** Mark your special occasions, such as birthdays, anniversaries, or engagements, by requesting donations in lieu of gifts. This inspiring way to celebrate contributes to fundraising for a cause close to your heart.



Corporate Support: Explore corporate philanthropy and partnerships to advance cancer research. Tax-deductible donations and strategic partnerships are vital in supporting patients, building capacity, and delivering meaningful benefits to our community.

Gifts In Will

Legacy Contributions: Transforming Futures

By including a gift to WARPNINE Incorporated in your Will, you play a crucial role in realising our vision of transforming pancreatic, gastrointestinal, and rare cancers into curable diseases. Your thoughtful contribution empowers us to confidently plan for the future, building upon Western Australia's world-leading outcomes in cancer care. In collaboration with Willed, a user-friendly platform, creating your Will through an online portal takes less than 20 minutes, offering a seamless and efficient process to leave a lasting impact on cancer research.

To learn more about how you can join our vital mission to extend precious time and hope to those impacted by pancreatic, gastro-intestinal, and rare cancers, please get in touch with us today. Your support has the power to create an extraordinary impact.

Meg Croucher

Chief Executive Officer

0406 818 810

admin@warpnine.org.au

warpnine.org.au

Financial Statements

For the financial year ended June 30, 2023



AUDITOR'S INDEPENDENCE DECLARATION

TO THE DIRECTORS OF WARPINE INCORPORATED

In accordance with the requirements of section 60-40 of the *Australian Charities and Not-for-profits Commission Act 2012*, as auditor for the audit of Warpine Incorporation for the year ended 30 June 2023, I declare that, to the best of knowledge and belief, there have been no contraventions of:

- the auditor independence requirements of *Australian Charities and Not-for-profits Commission Act 2012* in relation to the audit; and
- any applicable code of professional conduct in relation to the audit.

Reliance Auditing Services

Reliance Auditing Services (WA) Pty Ltd

A handwritten signature in black ink that reads "Naz Randeria".

Naz Randeria
Managing Director
Perth
11 December 2023



INDEPENDENT AUDITOR'S REPORT

To the Directors of Warpline Incorporated

Opinion

We have audited the financial report of Warpline Incorporated Ltd ('the Association'), which comprises the statement of financial position as at 30 June 2023, the statement of profit or loss and other comprehensive income, the statement of changes in equity, the statement of cash flows and notes to the financial statements, including a summary of significant accounting policies and the Directors' Declaration.

In our opinion, the accompanying financial report of the Company is in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- giving a true and fair view of the Company's financial position as at 30 June 2023 and of its financial performance for the year then ended; and
- complying with Australian Accounting Standards to the extent described in Note 2, and Division 60 of the *Australian Charities and Not-for-profits Commission Regulations 2022*.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Company in accordance with the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* ('the Code') that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter – Basis of Accounting

We draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report has been prepared for the purpose of fulfilling the Company's financial reporting responsibilities under the *Australian Charities and Not-for-profits Commission Act 2012* ('the ACNC Act'). As a result, the financial report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.

Responsibilities of the Directors for the Financial Report

The Directors is responsible for the preparation of the financial report that gives a true and fair view and have determined that the basis of preparation described in Note 1 to the financial report is appropriate to meet the requirements of the ACNC Act and is appropriate to meet the needs of the members.

The Directors' responsibility also includes such internal control as Directors determine is necessary to enable the preparation of a financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists.

Head Office

PO Box 767, West Perth WA 6872
Level 3 / 72 Kings Park Road, West Perth WA 6005

Melbourne

PO Box 670, North Melbourne VIC 3051

p 1300 291 060
e info@relianceauditing.com.au
w www.relianceauditing.com.au



Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with Australian Auditing Standards, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Directors.
- Conclude on the appropriateness of the Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Directors, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Independence

We confirm that the independence declaration required by the ACNC Act, which has been given to the Directors, would be the same terms if given to the Directors at the time of this auditor's report.

Reliance Auditing Services

Reliance Auditing Services (WA) Pty Ltd

A handwritten signature in black ink that reads "Randeria".

Naz Randeria
Managing Director
Perth
11 December 2023

Warpnine Incorporated
Statement of Financial Position
as at 30 June 2023

	<i>Note</i>	2023	2022
		\$	\$
Current Assets			
Cash at Bank		823,041	546,428
Prepayments		6,658	-
Total Current Assets		829,699	546,428
Total Assets		829,699	546,428
Current Liabilities			
Other Creditors		10,639	5,724
Provisions		19,314	-
Total Current Liabilities		29,953	5,724
Total Liabilities		29,953	5,724
NET ASSETS		799,746	540,704
Funds retained		799,746	540,704
TOTAL EQUITY		799,746	540,704

This statement should be read in conjunction with the notes to the financial statements.
Full audited report available via the ACNC website.

Warpline Incorporated
Statement of Comprehensive Income

for the year ended 30 June 2023

	<i>Note</i>	2023	2022
		\$	\$
Income			
Donations		590,882	610,578
Total Income		590,882	610,578
Expenditure			
Accounting		990	360
Advertising & Marketing		6,361	4,794
Audit Fees		3,200	-
Entertainment		438	80
Freight, Courier & Postage		666	124
Insurance		7,227	-
Legal Fees		603	-
Office Supplies		-	730
Operational Expenses		11,439	-
Payroll Expenses		194,757	63,174
Subscriptions & Memberships		3,042	552
Travel		412	60
Total Expenses		229,135	69,875
Funding Contributions	3	102,705	-
Operating surplus for the year		259,042	540,703
Other Comprehensive Income		-	-
Total Comprehensive Income for the year		259,042	540,703

This statement should be read in conjunction with the notes to the financial statements.
 Full audited report available via the ACNC website.

Warpnine Incorporated
Statement of Cash flows
for the year ended 30 June 2023

	Note	2023 \$	2022 \$
Cashflow from Operating Activities			
Receipts from donations		590,882	610,578
Payments to suppliers and employees		(211,564)	(64,150)
Funding contributions		(102,705)	-
Net cash flows from operating activities		276,613	546,428
Net Increase/(decrease) in cash and cash equivalents		276,613	546,428
Cash and cash equivalents at the beginning of year		546,428	-
Cash and cash equivalents at the end of year		823,041	546,428

This statement should be read in conjunction with the notes to the financial statements.
 Full audited report available via the ACNC website.



Charging at warp speed to find the cancer treatments of the future!

www.warpnine.org.au

e: admin@warpnine.org.au

ABN: 25 683 900 655

Charitable Collections License: 23030